Executive Summary

The U.S. shingles prevention market is centered on one currently available recombinant vaccine. Its regulatory record extends well beyond the original 2017 approval and now includes use in adults at increased risk because of immunodeficiency or immunosuppression, postmarketing safety actions, long term follow up data, concomitant vaccination information, and a liquid prefilled syringe presentation.

The commercial position remains substantial in 2026. U.S. turnover reached $850 million during the first six months of the year using GSK's convenience translation, and cumulative U.S. immunization reached 45%. The geographic mix continues to change, with European turnover exceeding U.S. turnover during the same period.

Active shingles has an established antiviral treatment pathway, while postherpetic neuralgia has separate approved pharmacologic options. For development programs, prevention, acute viral treatment, and persistent neuropathic pain represent materially different regulatory settings with different evidence requirements and competitive benchmarks.

Varicella zoster virus and shingles

Varicella-zoster virus (VZV) is an exclusively human alphaherpesvirus. Primary infection typically causes varicella, or chickenpox. After primary infection, VZV establishes lifelong latency in ganglionic neurons and can later reactivate as herpes zoster, or shingles, particularly as VZV-specific immune control declines with age or immunosuppression. 123

Shingles typically causes a painful vesicular rash in one or two adjacent dermatomes and most often affects the trunk or face. Centers for Disease Control and Prevention (CDC) estimates that about 1 in 3 people in the United States will develop herpes zoster during their lifetime and that approximately 1 million cases occur annually. Risk increases with age and weakened immunity. Postherpetic neuralgia is the most common complication and occurs in approximately 10% to 18% of people with herpes zoster. 134

Regulatory status in 2026

Shingrix, formally Zoster Vaccine Recombinant, Adjuvanted, was originally approved by the U.S. Food and Drug Administration (FDA) on October 20, 2017 under Biologics License Application (BLA) 125614. The original BLA was submitted under section 351(a) of the Public Health Service (PHS) Act and authorized the vaccine for prevention of herpes zoster in adults aged 50 years and older. FDA's Purple Book continues to identify BLA 125614 as a section 351(a) license. 56

The publicly available Shingrix development and approval pathway information can also be explored in Regulatory Designer, which maps disclosed clinical and regulatory milestones across the program.

The current indication is broader than the original 2017 indication. The February 2026 prescribing information indicates the vaccine for prevention of herpes zoster in adults aged 50 years and older and in adults aged 18 years and older who are or will be at increased risk because of immunodeficiency or immunosuppression caused by known disease or therapy. The label contains a limitation of use for prevention of primary varicella infection. 7

The current label describes two 0.5 mL intramuscular doses. The standard interval is 2 to 6 months. Individuals who are or will be immunodeficient or immunosuppressed and would benefit from completing vaccination sooner may receive the second dose 1 to 2 months after the first. The product is supplied as a vial and vial presentation requiring reconstitution and as a prefilled syringe that does not require reconstitution. 7

Zostavax, Zoster Vaccine Live, was originally approved on May 25, 2006 under BLA 125123. FDA's Purple Book lists its marketing status as discontinued, and the CDC states that it has not been available for use in the United States since November 18, 2020. 89

A regulatory history built through supplements

The original October 2017 approval established a recombinant glycoprotein E vaccine used with the AS01B adjuvant system for adults aged 50 years and older. FDA's approval letter also established three postmarketing commitments: Study Zoster-062 in adults with a prior episode of herpes zoster, U.S. targeted safety study EPI-ZOSTER-030, and Study Zoster-049 to assess long term efficacy, immunogenicity, and safety. 5

The regulatory record then expanded through a series of supplemental BLAs. The March 2021 supplement added new Guillain-Barré syndrome safety information. The July 2021 efficacy supplement expanded the indication to adults aged 18 years and older at increased risk because of immunodeficiency or immunosuppression. Subsequent supplements added concomitant vaccination and revaccination data, long term effectiveness information, a liquid prefilled syringe presentation, and additional postmarketing safety information. 101112131415

The evidence behind the current indication

For the original population aged 50 years and older, the current prescribing information reports 97.2% efficacy against confirmed herpes zoster, with a 95% confidence interval of 93.7% to 99.0%. The modified total vaccinated cohort included 7,344 vaccine recipients and 7,415 placebo recipients; 6 confirmed cases occurred in the vaccine group and 210 in the placebo group. 7

The 2021 indication expansion was submitted as efficacy supplement BLA 125614/398. FDA approved use in adults aged 18 years and older who are or will be at increased risk because of immunodeficiency or immunosuppression, and the approval letter identifies six associated clinical trials. FDA also waived the Pediatric Research Equity Act pediatric study requirement for the supplement and established a postmarketing commitment to evaluate pregnancy and birth outcomes in immunodeficient or immunosuppressed women aged 18 to 49 years, with a final report milestone of December 31, 2029. 11

The current label reports direct efficacy data in selected immunocompromised populations. Among autologous hematopoietic stem cell transplant (auHSCT) recipients aged 18 years and older, efficacy against herpes zoster was 68.2%, with a 95% confidence interval of 55.5% to 77.6%. The analysis included 870 vaccine recipients and 851 placebo recipients. A post hoc efficacy analysis in 515 subjects with hematologic malignancies reported 87.2% efficacy, with a 95% confidence interval of 44.2% to 98.6%. 7

Longer follow up subsequently entered the U.S. label. Study Zoster-049 was one of the postmarketing commitments established at original approval, and FDA approved supplement BLA 125614/1022 on March 21, 2025 to add information from that study and recorded the commitment as fulfilled. The current prescribing information describes 7,273 subjects followed for herpes zoster and postherpetic neuralgia beginning at a median of 5.6 years after vaccination and ending at a median of 11.4 years after vaccination. 5137

The long term study was open label and followed prior vaccine recipients from the original studies. The current label reports age specific herpes zoster incidence rates of 1.0, 1.3, 2.3, and 2.5 per 1,000 person years for participants who had been aged 50 to 59, 60 to 69, 70 to 79, and 80 years or older at vaccination, respectively. The label presents these incidence data in the context of rates observed in the earlier vaccine and placebo groups. 7

Postmarketing safety changed the label

Guillain-Barré syndrome (GBS) provides a clear example of the postapproval evidence cycle. FDA approved supplement BLA 125614/464 on March 24, 2021 to update Warnings and Precautions and Adverse Reactions with new GBS safety information. The approval followed a January 22, 2021 FDA Safety Labeling Change Notification under section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act concerning an increased risk observed during the 42 days after vaccination in a postmarketing observational study. 10

FDA's March 2021 public safety communication stated that the observational findings showed an association while the available evidence was insufficient at that time to establish a causal relationship. The February 2026 prescribing information incorporates two Medicare based observational analyses and states that the results of each suggest a causal association. 167

In the first analysis, the current label reports an estimated 3 excess GBS cases per million doses administered to adults aged 65 years and older during the 42 day period after vaccination. A secondary analysis estimated 6 excess cases per million after the first dose and found no increased risk after the second dose. The second observational study estimated 7 excess cases per million doses in its primary analysis and 12 excess cases per million following the first dose in a secondary analysis, again with no increased risk observed after the second dose. 7

The February 13, 2026 supplement, BLA 125614/1206, incorporated information from Study EPI-ZOSTER-032 into the postmarketing section, added injection site induration to postmarketing experience, and removed reference to a one dose carton for the vial and vial presentation. The GBS warning therefore originated in the 2021 safety action and was subsequently expanded with additional observational evidence in 2026. 1015

Product lifecycle changes continued in 2025

Two 2025 supplements illustrate regulatory lifecycle management beyond indication expansion. On March 21, 2025, FDA approved BLA 125614/1022 to update the prescribing information with Study Zoster-049 long term effectiveness information and recorded the associated postmarketing commitment as fulfilled. 13

On July 16, 2025, FDA approved BLA 125614/1131 for a liquid formulation presented in prefilled syringes. The approval letter identifies the formulation as gE/AS01B Liquid and establishes a 36 month dating period from manufacture when stored at 2°C to 8°C. The February 2026 prescribing information describes the prefilled syringe as ready for administration without reconstitution, while the vial presentation continues to require reconstitution of the lyophilized glycoprotein E antigen with the adjuvant suspension. 147

The May 2023 supplement added another layer to the label by incorporating safety and immune response data when the vaccine was administered concomitantly with Pneumovax 23, Prevnar 13, or Boostrix, as well as information following revaccination of people previously vaccinated with Zostavax. 12

FDA licensure and CDC policy are distinct layers

FDA approval established the original age 50 and older indication on October 20, 2017. Five days later, the Advisory Committee on Immunization Practices (ACIP) recommended recombinant zoster vaccine (RZV) for immunocompetent adults aged 50 years and older, recommended vaccination of adults in that age group who had previously received the live zoster vaccine, and preferred RZV over the live vaccine. The recommendation became official Centers for Disease Control and Prevention (CDC) policy in January 2018. 517

The age thresholds diverged again after the immunocompromised indication expansion. FDA approved the expanded indication beginning at age 18 on July 23, 2021. On October 20, 2021, ACIP voted 15 to 0 to recommend two RZV doses beginning at age 19 for adults who are or will be immunodeficient or immunosuppressed because of disease or therapy, using age 19 to align with the adult immunization schedule. 119

This distinction matters when describing the product's regulatory position. FDA defines the licensed indication and prescribing information, while CDC and ACIP define U.S. immunization recommendations. For immunocompromised adults, the licensed indication begins at age 18 and the routine CDC recommendation begins at age 19. 79

The 2026 U.S. commercial position

GSK reported £634 million of U.S. Shingrix turnover for the six months ended June 30, 2026, representing 3% growth at actual exchange rates (AER) and 7% growth at constant exchange rates (CER) compared with the first half of 2025. Global turnover during the same period was £1.914 billion. Europe contributed £895 million and International markets contributed £385 million. 18

GSK separately publishes an unaudited U.S. dollar convenience translation of its sterling results. On that basis, first half 2026 Shingrix turnover was $2.565 billion globally, including $850 million in the United States, $1.199 billion in Europe, and $516 million in International markets. These U.S. dollar amounts are translations of the reported sterling amounts using average rates for the period and should be read as convenience translations rather than separately reported local currency revenue. 19

Second quarter 2026 U.S. turnover was £245 million, up 2% at actual exchange rates and flat at constant exchange rates. GSK described U.S. sales as broadly stable, with lower demand and channel inventory utilization offset by favorable pricing, including prior period rebate adjustments. Those rebate adjustments added 3 percentage points to overall Shingrix growth in the quarter. 18

The uptake data show a mature U.S. vaccination market with additional eligible individuals remaining. GSK reported that cumulative U.S. immunization reached 45% by the end of the first quarter of 2026, up 3 percentage points from 12 months earlier, citing IQVIA data. 18

Acute shingles has an established antiviral pathway

Herpes zoster results from reactivation of varicella zoster virus (VZV). CDC identifies acyclovir, valacyclovir, and famciclovir as the three preferred antiviral drugs for initial treatment of shingles. CDC states that these therapies accelerate lesion resolution, reduce formation of new lesions and viral shedding, and decrease the severity of acute pain. 3

Treatment timing is clinically relevant. CDC states that treatment is most effective within 72 hours of symptom onset and emphasizes early treatment because progressive corneal involvement can threaten vision. 3

The cited public health source establishes the role of these agents in shingles care but does not provide shingles specific U.S. sales for 2026. Because these drugs are used in clinical settings beyond herpes zoster, total molecule sales would not provide a validated estimate of the shingles treatment market without indication level utilization data. 3

Postherpetic neuralgia has its own regulatory precedents

Postherpetic neuralgia (PHN) is a separate treatment setting after herpes zoster. Current FDA labeling includes systemic and topical products with PHN indications, including gabapentin, pregabalin, and capsaicin 8% topical systems. 202122

Neurontin is indicated for postherpetic neuralgia in adults. Lyrica is indicated for postherpetic neuralgia and its current label specifies dose adjustment in adults with reduced renal function. Qutenza is an 8% capsaicin topical system indicated for neuropathic pain associated with postherpetic neuralgia and is administered by a physician or other healthcare professional. 202122

The current labels also show the age of these regulatory precedents. The Neurontin label identifies initial U.S. approval in 1993, the Lyrica label identifies initial U.S. approval in 2004, and the Qutenza label identifies initial U.S. approval in 2009. Those dates refer to initial product approval and do not by themselves establish the approval date of each specific PHN claim. 202122

A validated 2026 U.S. PHN market total is unspecified in these FDA sources. Both gabapentin and pregabalin have labeled uses beyond PHN, so product level revenue cannot be assigned to shingles related neuropathic pain without indication specific commercial data. 2021

Regulatory implications for new development

A new shingles vaccine program would enter a setting defined by an approved section 351(a) biologic with 97.2% pivotal efficacy in adults aged 50 years and older, a licensed immunocompromised population, long term follow up extending to a median of 11.4 years after vaccination, a national immunization recommendation, and substantial current U.S. use. Those benchmarks make the proposed claim and target population central to development strategy. 7918

The regulatory history also shows several possible dimensions for lifecycle development. Since original approval, FDA has acted on an expanded population, a shorter dosing interval for specified immunocompromised individuals, concomitant vaccination data, long term effectiveness information, a new presentation, and evolving postmarketing safety evidence. Each change entered the regulatory record through a supplemental application or labeling action supported by a defined evidence package. 1112131415

The acute treatment setting presents a different program problem. CDC identifies three preferred antiviral agents and emphasizes treatment within 72 hours, placing timing of enrollment and treatment initiation directly into the clinical context for a new antiviral or adjunctive therapy. The sources cited here do not specify the endpoint package or effect size FDA would require for a new acute herpes zoster treatment. 3

For PHN, current FDA labels establish regulatory precedent across oral systemic therapy and healthcare administered topical therapy. A new program would need to define its intended pain claim, duration of treatment, target population, safety profile, administration setting, and evidence of clinically meaningful benefit in the context of these established therapies. 202122

Conclusion

The U.S. shingles landscape reflects an established product lifecycle rather than a static vaccine approval. The current vaccine began with a 2017 BLA for adults aged 50 years and older and subsequently accumulated an immunocompromised indication, postmarketing safety changes, additional coadministration evidence, long term follow up, and a new liquid presentation.

Its 2026 commercial performance confirms that these regulatory developments sit within a large active market. U.S. turnover remains substantial as vaccination penetrates further into the eligible population, while growth has become increasingly international.

Development opportunities depend on the intended point of intervention. Prevention programs face a strong efficacy and durability benchmark. Acute treatment programs must account for established antivirals and rapid treatment initiation. Postherpetic neuralgia programs enter a setting with several longstanding regulatory precedents for neuropathic pain. The regulatory strategy should begin with the proposed claim and the evidence needed to change one of those existing treatment or prevention decisions.